

CollyriuNP

Collyrium for the treatment of Age related Macular Degeneration (AMD)



Date 24/10/2025
Version: 02



CollyriuNP

Collyrium for the treatment of Age related Macular Degeneration (AMD)

Mission

CollyriuNP for treating AMD and other inherited retinal diseases using biocompatible nanoparticles

Sector: Therapeutics

Potential indications

- Age related Macular Degeneration
- Inherited retinal diseases

Market

In Spain, more than 750,000 patients, and more than 3 million at risk of developing it. Globally, the AMD market was valued at USD 10 billion in 2024 and was projected to exhibit 7% CAGR from 2025-2034

Financial needs: 2 M €

Use of funds



Preclinical regulatory

PROBLEM

- AMD is the major cause of blindness in adults.
- Chronic inflammation, Reactive Oxygen Species (ROS) and oxidative stress are one of the main mechanisms of disease progression
- There are no treatments beyond reducing risk factors (smoking, cholesterol, hypertension or sun exposure)
- Current antioxidant therapies lack of effectiveness

SOLUTION

- Ophthalmic formulation of Cerium Oxide nanoparticles (CeO₂) to stop the progression of AMD and other retinal diseases related to oxidative stress.
- CeO₂ nanoparticles act as a non-exhausting catalyst of reactive oxygen species conversion, drastically reducing chronic tissue inflammation.
- Effectiveness tested successfully both dry and wet AMD in mice models, as well as repeated dose toxicity.

COMPETITIVE ADVANTAGE

- Formulation and medical uses of CeO₂ protected by patent
- Scalable synthesis under GMP standards
- Formulation for cornea penetration and intravitreal retention
- Biocompatible, biodegradable, and non-metabolized
- Used already in medical products such as sunscreens, cosmetics, and toothpastes

ROADMAP

	2026				2027			
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
Preclinical regulatory								
Regulatory submission								

TEAM



Dr. Victor Franco Puentes
Pharmacokinetic nanoparticles group
Vall d'Hebron Institute of Research
Scientific Leader



Dr. Anna Duarri Piqué
Ophthalmology Group
Vall d'Hebron Institute of Research
Scientific Leader



Dr. Miguel Angel Zapata
Ophthalmology department
Vall d'Hebron University Hospital
Clinical Leader



Dr. Edgar Fuentes
Innovation Manager
Vall d'Hebron Institute of Research
Valorization and technology transfer strategy

Additional info



PCT: PCT/EP2022/059891



Contact: innovacio@vhir.org



